Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 6

1.

Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy.

Meckel M, Nauth A, Timpe J, Zhernosekov K, Puranik AD, Baum RP, Rösch F.

Cancer Biother Radiopharm. 2015 Mar;30(2):94-9. doi: 10.1089/cbr.2014.1720. Epub 2015 Feb 25.

PMID:
25714451
2.

In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour models.

Meckel M, Fellner M, Thieme N, Bergmann R, Kubicek V, Rösch F.

Nucl Med Biol. 2013 Aug;40(6):823-30. doi: 10.1016/j.nucmedbio.2013.04.012.

PMID:
23915801
3.

(68)Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitter.

Fellner M, Biesalski B, Bausbacher N, Kubícek V, Hermann P, Rösch F, Thews O.

Nucl Med Biol. 2012 Oct;39(7):993-9. doi: 10.1016/j.nucmedbio.2012.04.007. Epub 2012 May 23.

PMID:
22633217
4.

PET/CT imaging of osteoblastic bone metastases with (68)Ga-bisphosphonates: first human study.

Fellner M, Baum RP, Kubícek V, Hermann P, Lukes I, Prasad V, Rösch F.

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):834. doi: 10.1007/s00259-009-1355-y. Epub 2010 Jan 13. No abstract available.

PMID:
20069291
5.

Lanthanide(III) complexes of bis(phosphonate) monoamide analogues of DOTA: bone-seeking agents for imaging and therapy.

Vitha T, Kubícek V, Hermann P, Elst LV, Muller RN, Kolar ZI, Wolterbeek HT, Breeman WA, Lukes I, Peters JA.

J Med Chem. 2008 Feb 14;51(3):677-83. doi: 10.1021/jm7012776. Epub 2008 Jan 9.

PMID:
18181563
6.

A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting.

Kubícek V, Rudovský J, Kotek J, Hermann P, Vander Elst L, Muller RN, Kolar ZI, Wolterbeek HT, Peters JA, Lukes I.

J Am Chem Soc. 2005 Nov 30;127(47):16477-85.

PMID:
16305234
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk